VRTX · VERTEX PHARMACEUTICALS INCORPORATED

Back to holdings

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

Close · 3M

+4.26%

Held by 2 AI ETFs

QRFT0.280%

as of Jul 8

PQUS0.230%

as of Jul 21

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals4

Win rate75% (3/4)

Avg buy return+1.77%

QRFTnow 0.280% of fund2 signals

QRFT · Weight increase · 2d

Vertex Pharmaceuticals' financial profile, with a Revenue Growth of 10.08% and a Return on Equity of 23.93%, likely indicated strong quality and operational efficiency for Qraft AI's selection within QRFT's broad large-cap core strategy. Despite a PER of 28.65 and PBR of 6.16, these figures, alongside the company's growth, align with the fund's AI methodology which incorporates traditional factors like value, momentum, and quality. The consecutive weight increase for VRTX, climbing from 0.2800% to 0.2900% on July 1st and 2nd, precisely coincided with the stock trading at $528.04, 100% of its 52-week range, following a 30-day return of +22.7%. This upward adjustment reflects the Qraft AI's emphasis on momentum and its proprietary alternative-data overlays, which likely identified sustained positive drivers for the Health Care sector constituent even at its recent peak.

weight 0.270% → 0.290% (+0.020 pp)·stock up 24.2% in the 30 days before

Jul 2·entry $528.04·now $480.50Fresh

-9.00%

since Jul 2

QRFT · Weight increase · 2d

weight 0.230% → 0.250% (+0.020 pp)·stock up 4.5% in the 30 days before

Jun 5·entry $446.83·now $480.50Drifting

+7.54%

since Jun 5

PQUSnow 0.230% of fund2 signals

PQUS · Weight increase · 2d

VRTX trades at $475.20, near 95% of its 52-week high, after seeing a 6.0% return over 30 days, though its 90-day performance was negative 3.3%, and the 1-year return is 5.0%. This price trajectory, showing a recent upward trend from a prior dip, likely attracted Pictet's AI ranking system, which evaluates US large-cap stocks within its universe. The AI system appears to have recognized VRTX's financial profile, characterized by a P/E of 27.4, P/B of 6.16, 10.08% revenue growth, and 23.93% return on equity, as compelling. Following a period of stable 0.26% allocation, the consecutive weight increases to 0.27% on June 24th and 0.28% on June 25th indicate the AI's re-evaluation, aligning with PQUS's periodic rebalancing and its strategy of layering sector-balance and concentration rules on top, suggesting a measured move to increase exposure in Health Care for this stock at its current valuation.

weight 0.260% → 0.280% (+0.020 pp)·stock up 10.2% in the 30 days before

Jun 25·entry $480.18·now $480.50Fresh

+0.07%

since Jun 25

PQUS · Weight increase · 2d

weight 0.250% → 0.270% (+0.020 pp)·stock up 4.5% in the 30 days before

Jun 7·entry $442.96·now $480.50Drifting

+8.47%

since Jun 7

AIEQno longer held2 signals

AIEQ · Exit · 1d

Amplify's AIEQ, leveraging IBM Watson NLP for its daily ranking across thousands of US equities, likely identified a shift in sentiment or fundamental signals surrounding VRTX. This AI-driven fund, known for its daily rebalancing and portfolio of 140-180 US stocks, removed VRTX from its holdings on 2026-07-01 following a period of incremental weight adjustments. The decision coincides with VRTX trading at $498.01, effectively at its 52-week high, following a 30-day return of +14.7%. Such a move indicates EquBot's risk overlay, informed by the NLP output, may have detected a plateau in positive drivers or an elevated valuation making the stock less attractive relative to other opportunities in its universe.

weight 0.150% → 0 (exited)·stock up 13.6% in the 30 days before

Jul 1·entry $498.01·now $480.50

-3.52%

since Jul 1

AIEQ · Sudden change · 1d

VERTEX PHARMACEUTICALS exhibits a PER of 26.44, PBR of 6.16, 10.08% revenue growth, and ROE of 23.93%, figures that contribute to the fundamental assessment within AIEQ’s hybrid stock selection framework. While these fundamentals provide a base, EquBot's IBM Watson NLP likely detected a material shift in market sentiment or a valuation concern for VRTX as the stock approached 90% of its 52-week high on May 30, 2026, especially after only posting a 1.4% return over the prior 30 days. The AI’s daily ranking, incorporating news, social posts, and other data, signaled a need for a change. Consequently, AIEQ’s risk overlay executed a sharp reduction, decreasing the position from 0.5100% to 0.1300% in line with the fund's daily rebalancing and high-turnover style.

weight 0.510% → 0.130% (-0.380 pp)·stock up 5.7% in the 30 days before

May 30·entry $438.40·now $480.50

+9.60%

since May 30

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.